

MERRILL GOOZNER

Merrill@Goozner.com

9404 Pin Oak Drive
Silver Spring, MD 20910

(b) (6)

Accomplished investigative and explanatory reporter, author, editor, and journalism educator:

- 25 years in the news business covering micro- and macro-economics; federal, state and local budgets; international economics; global trade; labor and economic development
- 10 years specializing in health economics with a special focus on cost-effective medicine, pharmaceuticals and innovation
- 3 years university-level teaching business and economics journalism
- 10 years management experience in public interest advocacy organizations
- Recognized expert in health care economics and policy, biotechnology and pharmaceuticals, Executive Branch health-related agencies, especially CMS and FDA, and research ethics

WORK EXPERIENCE:

Director, Integrity in Science Project Center for Science in the Public Interest

December 2003 to April 2009

- The Integrity in Science project worked to improve the ethical underpinnings of scientific research by analyzing conflicts of interest among scientists serving on advisory committees at federal agencies, including the FDA, EPA, CMS, and the Interior, Energy and Agriculture departments, in published research and in regulatory submissions.
- Worked to improve disclosure policies at scientific journals and in the media.
- Wrote and edited *Integrity in Science Watch*, a weekly online and email newsletter available at www.integrityinscience.org,
- Managing (b) (4) staffers who investigated conflicts of interest among scientific researchers. Produced six studies in five years.

Adviser, Food and Drug Administration

July 2008 to Present

- Consumer representative on the Pharmaceutical Science and Clinical Pharmacology Advisory Committee
- Also served on an ad-hoc basis on other advisory committees evaluating new drug applications and conducting risk assessments.

Independent Researcher, Writer

June 2000 to Present

Author *The \$800 Million Pill: The Truth Behind the Cost of New Drugs*, which investigated and explained innovation in the pharmaceutical industry (University of California Press, 2004)

- Independent contributor on diverse subjects (mostly health and economics) to various publications. Subspecialties: FDA coverage; cancer care; neglected diseases.
- Post 200+ articles each year on *GoozNews.com*, focused largely on health care-related issues; website attracts 500 - 1,000 visitors daily, including many leading physicians, medical educators, and regulators.

- Organized, taught business reporting training seminars for Reynolds Center on Business Journalism

Kaiser Media Fellow, 2001-2003; **Michigan Journalism Fellow**, 1995-1996

Masters in Journalism, Columbia University Graduate School of Journalism; 1982

Bachelor of Arts (with honors) in History, University of Cincinnati; 1975.

Professor of Journalism

New York University

September 2000 to September 2003

- Taught graduate students in the Business and Economics Reporting program.
- Developed, wrote and taught three graduate-level courses: The Social Impact of the Corporation – Covering Regulatory Agencies; Reporting Health Care Industries; Reporting the Global Economy.
- Freelance writing included articles in New York Times, Chicago Tribune and Los Angeles Times (op-eds), Fortune Small Business, Columbia Journalism Review, The American Prospect, The Washington Monthly, The Nation, Salon.com, Slate.com and Boston Magazine.

Correspondent

Chicago Tribune

January 1987 to June 2000

- Chief Economics Correspondent, 1998-2000 – focus on global currency crisis; covered Federal Reserve Board and Treasury; Social Security and Medicare crises
- Chief Financial Correspondent, 1996-1998 – Covered Fed and Treasury, Securities and Exchange Commission and bank regulators, and Wall Street
- Chief Asia Correspondent, 1991-95 – Reported from 15 countries, based in Tokyo; major focus: international trade
- Business and Economics Reporter, 1987-1991
- Coverage areas sampling: Fed, Treasury, micro- and macro-economics and policy, health care, Social Security, Capitol Hill, financial markets, national correspondence, foreign correspondence (reporting on all subjects from 15 different countries), labor, law, economic development, various industries . . . more than 2,000 bylined articles and a half dozen series over 14 years.

Associate Editor

Crain's Chicago Business August 1983 to January 1987

- Covered economic development, government-business relations and economics for the nation's leading regional business publication
- Coverage areas: industrial policy, urban affairs, education and job training.
- Conceived and executed two major series, including an award-winning investigation of Chicago City Hall minority contracting fraud.

From 1977 to 1981, worked in investigative journalism and as a researcher and writer for public interest groups and unions

AWARDS: Chicago Headline Club Peter Lisagor Award (1984, 1985, 1986, 1987, 1988, 1989; 1999); Jacob Scher Investigative Journalism Award (1986); Education Writers Association National Award (1988).

Sample of Publications

“Cancer Cure? Not Without A Course Correction,” *Science Progress* (online magazine, Center for American Progress), May 19, 2009 (<http://www.scienceprogress.org/2009/05/cancer/>)

“Multi-Drug Resistant Tuberculosis in Russia,” *Scientific American*, Aug. 25, 2008 (<http://www.sciam.com/report.cfm?id=tuberculosis-in-russia>) -- a four-part series

Testimony before the Institute of Medicine Panel on Conflict of Interest in Medical Research, Education, and Practice, March 13, 2008. Available at <http://www.iom.edu/?id=52497> (accessed May 30, 2009).

Book Review: “Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation” by Richard A. Epstein; *Depaul Journal of Health Care Law*, Vol. 10, No. 4 (Fall 2007).

“Stopping Hookworm,” *The Scientist*, July 2007

“Conflicts of Interest in the Drug Industry's Relationship with the Government,” 35 *Hofstra L. Rev.* 737 (2007).

“Beating Malaria,” *The Scientist*, December 2006

“FDA Woes,” *AARP Bulletin*, May 2006.

“Trial and Error: With some drug researchers hiding crucial data in clinical trials, there is a way to get better science on drug safety,” Op-Ed, *The Chicago Tribune*, Dec. 13, 2005.

“Spreading Fear Like A Virus,” Book Review of *Monster at Our Door* and *False Alarm*, Washington Post, Nov. 23, 2005, C09.

“Overdosed and Oversold,” Op-Ed, *The New York Times*, December 21, 2004.

“Higher Skills, Fewer Jobs: With advanced technology and skilled workers, America can keep a strong manufacturing sector, but rising productivity equals a smarter – and smaller – work force,” *The American Prospect*, January 2004.

“Blinded By The Boom: What’s missing in the coverage of the New Economy,” *Columbia Journalism Review*, Nov./Dec. 2000 (<http://www.cjr.org/year/00/4/gozner.asp>)

“Duo only partially right about the U.S. tax problem,” book review of *The Great American Tax Dodge*, by Donald L. Barlett and James B. Steele in the *Philadelphia Inquirer*, Oct. 29, 2000.

“The Grateful Fed,” a review of *Greenspan: The Man Behind Money*, by Justin Martin in the *Washington Monthly*, November 2000 (<http://www.washingtonmonthly.com/books/2000/0011/gozner.html>)

“Summers’ Time,” Boston Magazine, May 1999
(<http://www.bostonmagazine.com/highlights/summerstime.shtml>)